Top Five Studied
Disease Areas in 2024
Phesi’s Annual Global
Analysis of Clinical Development
DOWNLOAD THE REPORT BELOW
Our annual global clinical development analysis leverages data from 132 million patients using Phesi's Trial Accelerator™ platform. This year's analysis of 67,469 recruiting clinical trials shows that breast cancer is the world’s most studied disease for the fourth year running - followed by solid tumors, stroke, prostate cancer and non-small cell lung cancer. The data reveals that one in three clinical trials were terminated during Phase II, a 50% increase from pre-COVID 19 levels. This represents tens of millions of dollars wasted on trials that ultimately fail that could be saved by using data science, AI and clinical data analytics to deliver greater precision in trial design and execution.
Key areas covered:
- Top Five Studied Disease Areas
- Highlights of Trial Innovation
- Phase 11 Attrition Rates
- Implications for Trial Design and Execution
Get your copy of the full report
Get our latest content
Trial Complexity report
Our new Impact of Clinical Trial Complexity on ROI report shows overcollection of data adds months to clinical trials, increases patient burden and reduces ROI. It highlights the need for protocol design optimization and for sponsors to ensure they do not include an unnecessarily large number of outcome measures.
Digital Patient Profile Catalogue
Leveraging global data from more than 132 million patients, Trial Accelerator™ generate a detailed picture of the patient for any indication, ensuring greater precision in trial design and execution.
Nature Publication
Read our Nature publication to discover the potential of AI-powered digital twins to replace external control arms in clinical trials.